Prasterone in the treatment of mild to moderate urge incontinence: an observational study

Abstract

ObjectiveTo assess the effects of prasterone compared with hyaluronic acid on symptoms of mild to moderate urinary urgency in women with genitourinary syndrome of menopause.MethodsThis is an observational prospective cohort study. A total of 58 postmenopausal women were enrolled (from December 2019 to May 2021). Overactive Bladder Screener questionnaire, Patient Global Impression of Improvement questionnaire, International Consultation on Incontinence Questionnaire–Short Form, and International Quality of Life questionnaire were used.ResultsFifty-eight women, 29 (50%) and 29 (50%), were treated with prasterone and hyaluronic acid for 12 weeks, respectively. At the end of the study, 26 (89.7%) versus 3 (10.3%) women reported an improvement (Patient Global Impression of Improvement score ≤3) of the symptoms in the prasterone versus hyaluronic acid group. According to the International Consultation on Incontinence Questionnaire–Short Form, no statistically significant difference was recorded before treatment between the prasterone and hyaluronic acid groups (median, 12 [6-12] vs 11 [8-12]; P = 0.8). Conversely, a statistically significant difference was recorded after treatment between the two groups (median, 8 [5-11] vs 10 [8-11]; P = 0.03). According to the International Quality of Life, a statistically significantly lower median score was recorded in the prasterone compared with the hyaluronic acid group, before (73 [interquartile range {IQR}, 55-81] vs 89 [IQR, 67-94]; P < 0.01) and after (78 [IQR, 65-86] vs 87 [IQR, 72-99]; P = 0.04) treatment.ConclusionsThe current observational study supports the hypothesis that prasterone might improve the severity of urinary urge incontinence in this set of women. However, these results need to be confirmed in further studies with a controlled design and a larger population.

New Possibilities for Hormonal Vaginal Treatment in Menopausal Women

“…Their study suggested that 12 weeks of prasterone treatment may have a positive impact on the severity of urinary urge incontinence in women, although it should be noted that the study was conducted on a small group of patients. It is worth noting that 89.7% of women reported a reduction in the discomfort of urgency in the prasterone group compared to the hyaluronic acid group, as assessed by the Patient Global Impression of Improvement score ≤3 [75]. However, there is currently no available data on the effect of short-term local vaginal prasterone treatment for stress urinary incontinence.…”

TOT in combination with solifenacin or intravaginal prasterone in postmenopausal women with mixed urinary incontinence: A retrospective analysis in 112 patients

“…It leads to positive effects on vulvovaginal atrophy (VVA) through the activation of vaginal androgen and estrogen receptors. Empirical evidence in this study suggests that intravaginal prasterone administration (dosage 6.5 mg) could be an effective treatment for postmenopausal women with genitourinary syndrome of menopause (GSM) affected by overactive bladder (OAB) 6,7 …”

“…Empirical evidence in this study suggests that intravaginal prasterone administration (dosage 6.5 mg) could be an effective treatment for postmenopausal women with genitourinary syndrome of menopause (GSM) affected by overactive bladder (OAB). 6,7 The aim of this study was to compare the efficacy of the transobturator tape (TOT) procedure combined with solifenacin (TOT-S) versus prasterone (TOT-P) in postmenopausal women affected by MUI with a predominant SUI component. A secondary endpoint was quality of life and sexual function evaluation.…”